company background image
IART

Integra LifeSciences Holdings NasdaqGS:IART Stock Report

Last Price

US$55.73

Market Cap

US$4.7b

7D

1.3%

1Y

-22.0%

Updated

06 Aug, 2022

Data

Company Financials +
IART fundamental analysis
Snowflake Score
Valuation4/6
Future Growth1/6
Past Performance1/6
Financial Health3/6
Dividends0/6

IART Stock Overview

Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, and general surgery.

Integra LifeSciences Holdings Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Integra LifeSciences Holdings
Historical stock prices
Current Share PriceUS$55.73
52 Week HighUS$76.70
52 Week LowUS$51.21
Beta1.09
1 Month Change2.86%
3 Month Change-5.73%
1 Year Change-21.98%
3 Year Change-11.26%
5 Year Change12.54%
Change since IPO1,104.97%

Recent News & Updates

Jul 27

Integra LifeSciences Holdings GAAP EPS of $0.54 beats by $0.09, revenue of $398M beats by $2.62M

Integra LifeSciences Holdings press release (NASDAQ:IART): Q2 GAAP EPS of $0.54 beats by $0.09. Revenue of $398M (+2.1% Y/Y) beats by $2.62M. Six-month revenues for 2022 were $774 million and increased 3.3% on a reported basis and 5.2% on an organic basis compared to the prior year. The Company is tightening its previous full-year 2022 organic growth guidance of 3.8% to 5.2% to an updated range of 4.0% to 5.2%, reflecting better than expected first half performance. Full-year 2022 reported revenue guidance is updated to a range of $1,557 million to $1,575 million representing reported growth of 1.0% to 2.1%, inclusive of the planned sale of the TWC business and an updated foreign currency outlook. Adjusted earnings per share guidance range is updated accordingly to $3.21 to $3.29.

Shareholder Returns

IARTUS Medical EquipmentUS Market
7D1.3%2.4%1.0%
1Y-22.0%-21.6%-12.9%

Return vs Industry: IART matched the US Medical Equipment industry which returned -21.6% over the past year.

Return vs Market: IART underperformed the US Market which returned -12.8% over the past year.

Price Volatility

Is IART's price volatile compared to industry and market?
IART volatility
IART Average Weekly Movement4.4%
Medical Equipment Industry Average Movement9.8%
Market Average Movement7.9%
10% most volatile stocks in US Market17.1%
10% least volatile stocks in US Market3.2%

Stable Share Price: IART is less volatile than 75% of US stocks over the past 3 months, typically moving +/- 4% a week.

Volatility Over Time: IART's weekly volatility (4%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19893,800Jan De Wittehttps://www.integralife.com

Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, and general surgery. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as asset management software and support, and after-market services.

Integra LifeSciences Holdings Fundamentals Summary

How do Integra LifeSciences Holdings's earnings and revenue compare to its market cap?
IART fundamental statistics
Market CapUS$4.65b
Earnings (TTM)US$166.30m
Revenue (TTM)US$1.57b

28.0x

P/E Ratio

3.0x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
IART income statement (TTM)
RevenueUS$1.57b
Cost of RevenueUS$570.60m
Gross ProfitUS$996.24m
Other ExpensesUS$829.94m
EarningsUS$166.30m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)1.99
Gross Margin63.58%
Net Profit Margin10.61%
Debt/Equity Ratio93.4%

How did IART perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is IART undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for IART?

Other financial metrics that can be useful for relative valuation.

IART key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue3.8x
Enterprise Value/EBITDA14.6x
PEG Ratio3.1x

Price to Earnings Ratio vs Peers

How does IART's PE Ratio compare to its peers?

IART PE Ratio vs Peers
The above table shows the PE ratio for IART vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPEEstimated GrowthMarket Cap
Peer Average40.2x
OMCL Omnicell
79.6x46.2%US$4.8b
NVST Envista Holdings
28.2x19.1%US$6.7b
ENOV Enovis
12.6x8.2%US$3.2b
GMED Globus Medical
40.4x14.1%US$6.3b
IART Integra LifeSciences Holdings
28x9.0%US$4.7b

Price-To-Earnings vs Peers: IART is good value based on its Price-To-Earnings Ratio (28x) compared to the peer average (40.2x).


Price to Earnings Ratio vs Industry

How does IART's PE Ratio compare vs other companies in the US Medical Equipment Industry?

Price-To-Earnings vs Industry: IART is good value based on its Price-To-Earnings Ratio (28x) compared to the US Medical Equipment industry average (33.9x)


Price to Earnings Ratio vs Fair Ratio

What is IART's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

IART PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio28x
Fair PE Ratio25.2x

Price-To-Earnings vs Fair Ratio: IART is expensive based on its Price-To-Earnings Ratio (28x) compared to the estimated Fair Price-To-Earnings Ratio (25.2x).


Share Price vs Fair Value

What is the Fair Price of IART when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: IART ($55.73) is trading below our estimate of fair value ($97.04)

Significantly Below Fair Value: IART is trading below fair value by more than 20%.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Target price is less than 20% higher than the current share price.


Discover undervalued companies

Future Growth

How is Integra LifeSciences Holdings forecast to perform in the next 1 to 3 years based on estimates from 11 analysts?

Future Growth Score

1/6

Future Growth Score 1/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


9.0%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: IART's forecast earnings growth (9% per year) is above the savings rate (1.9%).

Earnings vs Market: IART's earnings (9% per year) are forecast to grow slower than the US market (12.8% per year).

High Growth Earnings: IART's earnings are forecast to grow, but not significantly.

Revenue vs Market: IART's revenue (4.4% per year) is forecast to grow slower than the US market (7.9% per year).

High Growth Revenue: IART's revenue (4.4% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: IART's Return on Equity is forecast to be low in 3 years time (15.3%).


Discover growth companies

Past Performance

How has Integra LifeSciences Holdings performed over the past 5 years?

Past Performance Score

1/6

Past Performance Score 1/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


26.9%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: IART has a large one-off loss of $58.1M impacting its June 30 2022 financial results.

Growing Profit Margin: IART's current net profit margins (10.6%) are lower than last year (13.6%).


Past Earnings Growth Analysis

Earnings Trend: IART's earnings have grown significantly by 26.9% per year over the past 5 years.

Accelerating Growth: IART's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: IART had negative earnings growth (-19.1%) over the past year, making it difficult to compare to the Medical Equipment industry average (2%).


Return on Equity

High ROE: IART's Return on Equity (10%) is considered low.


Discover strong past performing companies

Financial Health

How is Integra LifeSciences Holdings's financial position?

Financial Health Score

3/6

Financial Health Score 3/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Debt Coverage

  • Interest Coverage

Financial Position Analysis

Short Term Liabilities: IART's short term assets ($1.1B) exceed its short term liabilities ($295.6M).

Long Term Liabilities: IART's short term assets ($1.1B) do not cover its long term liabilities ($1.8B).


Debt to Equity History and Analysis

Debt Level: IART's net debt to equity ratio (66.2%) is considered high.

Reducing Debt: IART's debt to equity ratio has reduced from 98.8% to 93.4% over the past 5 years.

Debt Coverage: IART's debt is not well covered by operating cash flow (17%).

Interest Coverage: IART's interest payments on its debt are well covered by EBIT (6.8x coverage).


Balance Sheet


Discover healthy companies

Dividend

What is Integra LifeSciences Holdings's current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate IART's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate IART's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if IART's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if IART's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as IART has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

3.8yrs

Average management tenure


CEO

Jan De Witte (58 yo)

0.67

Tenure

US$899,079

Compensation

Mr. Jan De Witte has been President, Chief Executive Officer & Director of Integra LifeSciences Holdings Corporation since December 1, 2021. He had been the Chief Executive Officer at Barco NV since Septem...


CEO Compensation Analysis

Compensation vs Market: Jan's total compensation ($USD899.08K) is below average for companies of similar size in the US market ($USD6.58M).

Compensation vs Earnings: Insufficient data to compare Jan's compensation with company performance.


Leadership Team

Experienced Management: IART's management team is considered experienced (3.8 years average tenure).


Board Members

Experienced Board: IART's board of directors are considered experienced (9.1 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: IART insiders have only sold shares in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Integra LifeSciences Holdings Corporation's employee growth, exchange listings and data sources


Key Information

  • Name: Integra LifeSciences Holdings Corporation
  • Ticker: IART
  • Exchange: NasdaqGS
  • Founded: 1989
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Implied Market Cap: US$4.654b
  • Shares outstanding: 83.50m
  • Website: https://www.integralife.com

Number of Employees


Location

  • Integra LifeSciences Holdings Corporation
  • 1100 Campus Road
  • Princeton
  • New Jersey
  • 8540
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/08/06 00:00
End of Day Share Price2022/08/05 00:00
Earnings2022/06/30
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.